ABSTRACT: RNA sequencing (RNA-seq) from FFPE samples is considered more challenging than DNA sequencing because RNA is more labile than DNA and get compromised in the FFPE process. Furthermore, a key component in analyzing the RNA-seq data involve quantitation in order to interpret the data in a clinical context and it adds one more valuable compared to the more binary DNA analysis for mutations. Finally, it is well known in the literature that the more the RNA is fragmented, the more artifacts in the dataset, such as ampli cation bias. In this presentation, we will discuss:
RNA extraction from FFPE tissue, and how we get highly reproducible data
RNA-seq leading to lifesaving treatment decisions
How RNA-seq can become a more important marker species than DNA
We have worked closely with Beckman Coulter on this project and are exited to share our findings testing numerous approaches and how they impact yield, RNA quality and ultimately data quality.
Presenters
Kind Regards
Gitte Pedersen,
CEO Genomic Expression
